ReviewBehavioural pharmacology2008
Developmental effects of 3,4-methylenedioxymethamphetamine: a review.
Review in Behavioural pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 65 citations in OpenAlex.
- Neurobehavioral disorders among children born to mothers exposed to illicit substances during pregnancy.BMC medicine · 2024Article
- MDPV (3,4-methylenedioxypyrovalerone) administered to mice during development of the central nervous system produces persistent learning and memory impairments.Pharmacological reports : PR · 2024Article
- Review
- Gestational Exposure to the Synthetic Cathinone Methylenedioxypyrovalerone Results in Reduced Maternal Care and Behavioral Alterations in Mouse Pups.Frontiers in neuroscience · 2018Article
- Developmental outcomes of 3,4-methylenedioxymethamphetamine (ecstasy)-exposed infants in the UK.Human psychopharmacology · 2015Article
- Developmental consequences of fetal exposure to drugs: what we know and what we still must learn.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Review
- Altered energy production, lowered antioxidant potential, and inflammatory processes mediate CNS damage associated with abuse of the psychostimulants MDMA and methamphetamine.European journal of pharmacology · 2014Review
- Neuronal reorganization in adult rats neonatally exposed to (±)-3,4-methylenedioxymethamphetamine.Toxicology reports · 2014Article
- Psychiatric profiles of mothers who take Ecstasy/MDMA during pregnancy: reduced depression 1 year after giving birth and quitting Ecstasy.Journal of psychopharmacology (Oxford, England) · 2014Observational
- MDMA and heightened cortisol: a neurohormonal perspective on the pregnancy outcomes of mothers used 'Ecstasy' during pregnancy.Human psychopharmacology · 2014Review
- Sex-dependent psychoneuroendocrine effects of THC and MDMA in an animal model of adolescent drug consumption.PloS one · 2013Article
- Article
- Distinct periods of developmental sensitivity to the effects of 3,4-(±)-methylenedioxymethamphetamine (MDMA) on behaviour and monoamines in rats.The international journal of neuropsychopharmacology · 2012Article
- Neonatal methylphenidate does not impair adult spatial learning in the Morris water maze in rats.Neuroscience letters · 2011Article
- In-utero exposure to the popular 'recreational' drugs MDMA (Ecstasy) and Methamphetamine (Ice, crystal): preliminary findings.Clinics in developmental medicine · 2011Article
- Drug testing for newborn exposure to illicit substances in pregnancy: pitfalls and pearls.International journal of pediatrics · 2011Article
- ttime: an R package for translating the timing of brain development across mammalian species.Neuroinformatics · 2010Article
- Illicit drug use in late pregnancy associated with stillbirth and eclampsia.Obstetric medicine · 2010Article
- During pregnancy, recreational drug-using women stop taking ecstasy (3,4-methylenedioxy-N-methylamphetamine) and reduce alcohol consumption, but continue to smoke tobacco and cannabis: initial findings from the Development and Infancy Study.Journal of psychopharmacology (Oxford, England) · 2010Article
- Illicit substance use in pregnancy - a review.Obstetric medicine · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
+/-3,4-Methylenedioxymethamphetamine (MDMA) is a chemical derivative of amphetamine that has become a popular drug of abuse and has been shown to deplete serotonin in the brains of users and animals exposed to it. To date, most studies have investigated the effects of MDMA on adult animals. With a majority of users of MDMA being young adults, the chances of the users becoming pregnant and exposing the fetuses to MDMA are also a concern. Evidence to date has shown that developmental exposure to MDMA results in learning and memory impairments in the Morris water maze, a task known to be sensitive to hippocampal disruption, when the animals are tested as adults. Developmental MDMA exposure leads to hypoactivity in the offspring as adults but does not affect outcome on tests of anxiety. MDMA administration decreases pup weight, increases corticosterone and brain-derived neurotrophic factor levels during treatment while decreasing brain levels of serotonin; a decrease that initially dissipates and then reappears in adulthood. Neonatal MDMA exposure increases the sensitivity of the serotonin 1A receptor, a possible mechanism underlying the learning and memory deficits seen. Taken together, the evidence shows that MDMA exposure has adverse effects on the developing brain and behavior. The animal and human data on developmental MDMA exposure are reviewed and their public health implications discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.